Electroporation

AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

Retrieved on: 
Wednesday, May 22, 2019
Surgery, Health, Biotechnology, Clinical trials, Medical devices, Oncology, FDA, Branches of biology, Medicine, Biology, Medical physics, RTT, Interventional radiology, Irreversible electroporation, Medical technology, Surgical oncology, Prostate cancer, Electroporation, Nanoknife

The pilot study is intended to inform the design of a pivotal clinical study in the United States to support the approval of a future Premarket Approval Application (PMA).

Key Points: 
  • The pilot study is intended to inform the design of a pivotal clinical study in the United States to support the approval of a future Premarket Approval Application (PMA).
  • This pilot study represents the next step in our comprehensive approach to establish NanoKnife as a platform technology to treat numerous cancers and conditions.
  • Prostate cancer is the second leading cause of cancer death in American men1.
  • The NanoKnife System is a unique, minimally invasive technique that has been used to successfully treat focal prostate lesions through irreversible electroporation.

Altogen Biosystems Launched GMP Grade Liver Targeted Transfection Reagent for In Vivo Delivery of Biomolecules

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Research, Science, General Health, Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, Gene delivery, Laboratory techniques, Applied genetics, Transfection, Electroporation, Magnet-assisted transfection, Nucleofection

This efficient reagent was selected as the delivery vehicle of choice in several drug development programs; to better accommodate clinical programs, Altogen Biosystems announced the launch of real-time adaptive cGMP manufacturing of liver-targeted in vivo transfection reagent.

Key Points: 
  • This efficient reagent was selected as the delivery vehicle of choice in several drug development programs; to better accommodate clinical programs, Altogen Biosystems announced the launch of real-time adaptive cGMP manufacturing of liver-targeted in vivo transfection reagent.
  • This novel liver-targeted delivery system may enable groundbreaking transfection efficiency medical applications including gene and oligonucleotides therapy of liver cancers.
  • Altogen Biosystems liver-targeted in vivo transfection reagent features liposome-based microscopic compounds coated with biodegradable polymers and attached to nucleic acids.
  • Altogen Biosystems provides over 120 transfection products for biomedical research, including cell type-specific transfection reagents, electroporation kits, and in vivo tissue-targeted delivery reagents.

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

Retrieved on: 
Wednesday, May 1, 2019
Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Gene delivery, Laboratory techniques, Applied genetics, Peripheral blood mononuclear cell, Electroporation, CARMA, Transfection

The CARMA platform offers an innovative approach to cell-based therapies that can be applied in a broad range of diseases, including solid tumors.

Key Points: 
  • The CARMA platform offers an innovative approach to cell-based therapies that can be applied in a broad range of diseases, including solid tumors.
  • The manufacturing process for MCY-M11 utilizes MaxCyte's proprietary Flow Electroporation technology to transfect mRNA into fresh (i.e., unexpanded) peripheral blood mononuclear cells (PBMCs).
  • The entire CARMA manufacturing process allows for streamlined manufacturing providing a much needed faster turnaround of autologous cell therapy to patients.
  • MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial.

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

Retrieved on: 
Monday, April 8, 2019
Biology, IBM PC compatibles, Natural sciences, ATX, Electroporation, Gaithersburg, Maryland, Life sciences

GAITHERSBURG, Md., April 8, 2019 /PRNewswire/ --MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced todaythe launch of the new ExPERT technology platform.

Key Points: 
  • GAITHERSBURG, Md., April 8, 2019 /PRNewswire/ --MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced todaythe launch of the new ExPERT technology platform.
  • This family of instruments the ATx, STx and GTx represents the next generation of the industry's leading, clinically validated Flow Electroporation technology for complex cellular engineering.
  • With these additions to the product portfolio, MaxCyte continues its uncompromising focus on high performance cellular editing, while delivering feature enhancements that will enable customers to use a single unifying technology, from concept to commercialization.
  • With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products.

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

Retrieved on: 
Tuesday, April 2, 2019
Branches of biology, Medicine, Medical specialties, Immunology, Virotherapy, Immunotherapy, Cytokine, Electroporation, Cancer immunotherapy, Interleukin

"The data presented at AACR highlight OncoSec's potentially game-changing approach to drug development.

Key Points: 
  • "The data presented at AACR highlight OncoSec's potentially game-changing approach to drug development.
  • The foundation of our DNA-based immunotherapy relies on electroporation, which bypasses the pitfalls associated with viral vectors or systemic cytokines."
  • These independent evolutions of both components of OncoSec's proprietary cancer immunotherapy platformconverged in the design of its new product candidate, SPARK.
  • OncoSec's lead immunotherapy investigational product candidate TAVO (tavokinogene telseplasmid) enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.

Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

Retrieved on: 
Tuesday, March 26, 2019
Health, AIDS, Biotechnology, Genetics, Infectious diseases, Research, Science, Branches of biology, Biology, Biochemistry, Gene delivery, Molecular biology, Biotechnology, Immune system, Immunology, Electroporation, Plasmid, Monoclonal antibody, Ichor

Ichor Medical Systems, Inc. (Ichor) announced today that it has entered into a collaboration and research license agreement with AstraZeneca (LSE, SSE, NYSE: AZN) for the development and clinical assessment of plasmid DNA constructs.

Key Points: 
  • Ichor Medical Systems, Inc. (Ichor) announced today that it has entered into a collaboration and research license agreement with AstraZeneca (LSE, SSE, NYSE: AZN) for the development and clinical assessment of plasmid DNA constructs.
  • The plasmids will encode monoclonal antibodies developed by AstraZeneca and will be delivered using Ichors TriGrid Delivery System .
  • Under the terms of the agreement, Ichor will receive upfront and annual payments along with development milestones.
  • Ichor Medical Systems investigational TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans.

Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

Retrieved on: 
Friday, March 1, 2019
Supply chain management, Health, Biotechnology, Genetics, Oncology, Pharmaceutical, Manufacturing, Chemicals, Plastics, Packaging, Retail, Research, Veterinary, Science, Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Gene delivery, Laboratory techniques, DNA, Amplicon, Plasmid, Electroporation

Per the JDA, LineaRx and Takis/Evvivax will jointly develop linear DNA expression amplicons for TK7 and ConTRT, two of Takis/Evvivaxs anti-cancer vaccine candidates, utilizing LineaRxs validated linear DNA technology.

Key Points: 
  • Per the JDA, LineaRx and Takis/Evvivax will jointly develop linear DNA expression amplicons for TK7 and ConTRT, two of Takis/Evvivaxs anti-cancer vaccine candidates, utilizing LineaRxs validated linear DNA technology.
  • Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered to pre-clinical animal models via Takis/Evvivaxs proprietary electroporation technology.
  • Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinicalnucleicacid-basedtherapeutic drug candidates.
  • Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.

Global Electroporation Instruments Market 2018-2022: Market to Grow at a CAGR of 5.64% - High Demand for Biopharmaceuticals

Retrieved on: 
Tuesday, October 2, 2018
Economy, Biology, Biotechnology, Gene delivery, Molecular biology, Business, Electroporation, Microbiology, Market analysis, Compound annual growth rate, Pharmaceutical industry in India, Marketplace

The "Global Electroporation Instruments Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Electroporation Instruments Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Electroporation Instruments Market to grow at a CAGR of 5.64% during the period 2018-2022.
  • Global Electroporation Instruments Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • One trend affecting this market is the high demand for biopharmaceuticals.

Global Transfection Reagent And Equipment Market to 2022 - Key Players are Thermo Fisher Scientific, Promega, QIAGEN & F.Hoffmann-La Roche

Retrieved on: 
Friday, August 31, 2018
Biology, Molecular biology, Biotechnology, Gene delivery, Applied genetics, Laboratory techniques, Transfection, Electroporation

The global transfection reagent & equipment market size is expected to reach USD 1.08 billion by 2022, progressing at a CAGR of 7.4% during the forecast period.

Key Points: 
  • The global transfection reagent & equipment market size is expected to reach USD 1.08 billion by 2022, progressing at a CAGR of 7.4% during the forecast period.
  • Transfection technology is recognized as an integral part of research programs pertaining to thorough investigation of various chromosomal anomalies.
  • Hence, rising cancer prevalence of cancer as well as genetic conditions is anticipated to provide a fillip to the market.
  • Further Key Findings From the Report Suggest:
    On the basis of method, electroporation and liposomal transfection accounted for substantial cumulative share in the market.

The global transfection reagent & equipment market size is expected to reach USD 1.08 billion by 2022

Retrieved on: 
Wednesday, June 27, 2018
Biology, Molecular biology, Biotechnology, Biochemistry, Gene delivery, Laboratory techniques, Applied genetics, Transfection, Electroporation, Compound annual growth rate, Liposome

NEW YORK, June 27, 2018 /PRNewswire/ -- Transfection Reagent And Equipment Market Size, Share, & Trends Analysis Report By Product, By Method, By Application (Gene Expression, Protein Production, Cancer Research, Therapeutics), And Segment Forecasts, 2014 - 2022

Key Points: 
  • NEW YORK, June 27, 2018 /PRNewswire/ -- Transfection Reagent And Equipment Market Size, Share, & Trends Analysis Report By Product, By Method, By Application (Gene Expression, Protein Production, Cancer Research, Therapeutics), And Segment Forecasts, 2014 - 2022
    The global transfection reagent & equipment market size is expected to reach USD 1.08 billion by 2022 progressing at a CAGR of 7.4% during the forecast period.
  • Furthermore, funds and grants by funding and government bodies are likely to back the growth of the market.
  • Further Key Findings From the Report Suggest:
    On the basis of method, electroporation and liposomal transfection accounted for substantial cumulative share in the market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.